Novel Heart Failure Drug Combo Cuts CV Mortality More Than Enalapril (FREE)

By Joe Elia Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM LCZ696, an experimental compound that inhibits both angiotensin and neprilysin, "may well represent a new threshold" in treating heart failure, according to an editorialist in the New England Journal of Medicine. Neprilysin is an endopeptidase that degrades certain endogenous vasoactive peptides; its inhibition increases …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news